Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA — Stella

Home/MDS (Myelodysplastic Syndrome)/

View on ClinicalTrials.gov

Recruiting

Back to MDS (Myelodysplastic Syndrome) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu

Key details

Phase

Safety & dosing

Sponsor

The First Affiliated Hospital of Soochow University

Enrollment target

~66 participants

Started

January 2026

Primary completion

January 2028

Age range

18 Years – 65 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.